David M O'Malley, MD
Academic Title: Professor in the College of Medicine
Research Program: Translational Therapeutics
About Me
More info forI am a professor in the Department of Obstetrics and Gynecology at The Ohio State University College of Medicine and the director of the Division of Gynecologic Oncology at the OSUCCC – James, where I've been a faculty member since 2005. I completed my gynecologic oncology fellowship at Yale University and my residency at Case Western Reserve University (MetroHealth) and the Cleveland Clinic Foundation. I attended medical school at Wayne State and earned my undergraduate degree at the University of Notre Dame. I am the director for clinical research in gynecologic oncology, as well as the co-director of the gynecologic oncology phase I program. I also serve as the ORIEN physician liaison for The Ohio State University Comprehensive Cancer Center. I am active nationally as a committee member for the NCI Gynecologic Cancer Steering Committee’s Ovarian Task Force, NRG Oncology (Ovarian Cancer and Developmental Therapeutics Groups), the Society of Gynecologist Oncology and the American Society of Clinical Oncology. My passion for improving the care of patients with gynecologic cancers and my expertise in ovarian cancer resulted in my appointment to the panel of the National Comprehensive Cancer Network (NCCN) Guidelines for Ovarian Cancer, where I continue as an active participant. As a member of the Translational Therapeutics Program at the OSUCCC – James, my research is focused on identifying novel and innovative therapies for gynecologic cancers. I have designed, coordinated and published on all levels of clinical trials to include phase I, II and III studies with a special interest in novel compounds. I continue to work to improve the therapies (novel techniques/targets/immune therapy) as well as identify patients who would benefit (or not benefit) from different treatment options in ovarian and uterine cancer (specifically high-risk histologies) while minimizing side effects. The quest to improve patient outcomes has led me to my work on improving surgical techniques. Robotic-assisted, minimally invasive surgical techniques have been implemented in all aspects of practice, resulting in the publication of the improved outcomes and as an instructor on these techniques at a national level. I am honored and humbled to help care for the amazing women who are my patients and their families. Improving the care of women with gynecologic cancer through research has led to me being recognized with over 100 publications in the most respected scientific journals, including New England Journal of Medicine, Journal of Clinical Oncology, Lancet Oncology, JAMA Oncology and Nature Genetics. My compassionate nature and communication has been recognized with patient satisfaction that ranks at the very top for the country. My accomplishments have also resulted in being named as one of the Best/Top Doctors in America by U.S. News and World Report (Castle Connelly) and Best Doctors for multiple years. However, my greatest pride comes from my family, including my beautiful wife and our five amazing children.
Clinical Expertise
More info for- Cervical Cancer
- Gynecologic Cancers
- Reproductive Health
- Women's Health
- Vaginal Cancers
- Soft Tissue Cancers
- Endometrial Cancers
- Ovarian Cancers
- Vulvar Cancers
- Uterine Cancers
- Minimally Invasive Surgical Procedures
- Robotics
- Peritoneal Cancers
Research Interests
More info for- Obesity
- Weight Loss
- Carcinosarcoma
- Carcinoma
- Neoplasms
- Neutropenia
- Endometrial Neoplasms
- Hypersensitivity
- Lymphedema
- Ovarian Neoplasms
Where I See Patients
More info forThe Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
460 W. 10th Ave. Columbus, Ohio 43210 800-293-5066 Location InformationEducation & Training
More info forInternship - Obstetrics & Gynecology
- Case Western Reserve University Endodontics Residency
10900 Euclid Ave, Cleveland, OH
Residency - Obstetrics & Gynecology
- Case Western Reserve University Endodontics Residency
10900 Euclid Ave, Cleveland, OH
Medical School
- Wayne State University School of Medicine
320 E Canfield St, Detroit, MI
Fellowship - Gynecologic Oncology
- Yale University School Of Medicine
PO Box 208042, New Haven, CT
- Case Western Reserve University Endodontics Residency
Academic Office & Contact Information
More info forAcademic Office:
320 W 10th Ave
Columbus, Ohio 43210-1280Phone:
614-293-7642Email:
omalley.46@osu.eduReviews
More info forPatient Satisfaction Review
The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our
Patient Satisfaction Survey page The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.
Videos
More info forPublications
More info forOctober 25, 2024Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary.
Moore KN, Lorusso D, Oaknin A, Oza A, Colombo N, Van Gorp T, O'Malley DM, Banerjee S, Murphy CG, Harter P, Konecny GE, Pautier P, Method M, Wang Y, Coleman RL, Birrer M, Matulonis UA
Gynecol Oncol
October 16, 2024Obesity-induced extracellular vesicles proteins drive the endometrial cancer pathogenesis: therapeutic potential of HO-3867 and Metformin.
Sakaue T, Dorayappan KDP, Zingarelli R, Khadraoui W, Anbalagan M, Wallbillich J, Bognar B, Wanner R, Cosgrove C, Suarez A, Koga H, Maxwell GL, O'Malley DM, Cohn DE, Selvendiran K
Oncogene
October 7, 2024GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer.
Grisham R, Monk BJ, Van Nieuwenhuysen E, Moore KN, Fabbro M, O'Malley DM, Oaknin A, Thaker P, Oza AM, Colombo N, Gershenson D, Aghajanian CA, Choi CH, Lee YC, Mirza MR, Coleman RL, Cobb L, Harter P, Lustgarten S, Youssoufian H, Banerjee S
Int J Gynecol Cancer
August 21, 2024Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from PRIMA/ENGOT-OV26/GOG-3012 trial.
Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, Graybill W, Mirza MR, McCormick CC, Lorusso D, Moore RG, Freyer G, O'Cearbhaill RE, Heitz F, O'Malley DM, Redondo A, Shahin MS, Vulsteke C, Bradley WH, Haslund CA, Chase DM, Pisano C, Holman LL, Pérez MJR, DiSilvestro P, Gaba L, Herzog TJ, Bruchim I, Compton N, Shtessel L, Malinowska IA, González-Martín A
Ann Oncol
August 7, 2024Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: A review for the gynecologic oncologist.
Riedinger CJ, Sakach J, Maples JM, Fulton J, Chippior J, O'Donnell B, O'Malley DM, Chambers LM
Gynecol Oncol
July 31, 2024Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer.
O'Malley DM, Myers T, Wimberger P, Gorp TV, Redondo A, Cibula D, Nicum S, Rodrigues M, Backes FJ, Barlin JN, Lewin SN, Lim P, Pothuri B, Diver E, Banerjee S, Lorusso D
Future Oncol
July 18, 2024Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012.
Kamrava MR, Gonzalez-Martin A, Pothuri B, Vergote I, Graybill W, Mirza MR, McCormick C, Lorusso D, Freyer G, O'Malley DM, York W, Malinowska IA, Monk BJ
Gynecol Oncol
July 16, 2024Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer.
Monk BJ, Romero I, Graybill W, Churruca C, O'Malley DM, Knudsen AØ, Yap OWS, Baurain JF, Rose PG, Denys H, Ghamande S, Pisano C, Fabbro M, Braicu EI, Calvert PM, Amit A, Prendergast E, Taylor A, Kheibarshekan L, Zhang ZY, Zajic S, Jewell RC, Gupta D, González-Martín A
Clin Ther
July 1, 2024Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study.
Graybill WS, Pardo Búrdalo B, O'Malley DM, Vergote I, Monk BJ, Auranen A, Copeland LJ, Sabbatini R, Herzog TJ, Follana P, Pothuri B, Braicu EI, McCormick C, Yubero A, Moore RG, Vuylsteke P, Raaschou-Jensen N, York W, Hartman J, González-Martín A
Int J Gynecol Cancer
July 1, 2024Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer.
Olawaiye AB, Kim JW, Bagameri A, Bishop E, Chudecka-Glaz A, Devaux A, Gladieff L, Gordinier ME, Korach J, McCollum ME, Mileshkin L, Monk BJ, Nicum S, Nogueira-Rodrigues A, Oaknin A, O'Malley DM, Orlando M, Dreiling L, Tudor IC, Lorusso D
J Gynecol Oncol
May 16, 2024A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib.
Liu JF, Xiong N, Wenham RM, Wahner-Hendrickson A, Armstrong DK, Chan N, O'Malley DM, Lee JM, Penson RT, Cristea MC, Abbruzzese JL, Matsuo K, Olawaiye AB, Barry WT, Cheng SC, Polak M, Swisher EM, Shapiro GI, Kohn EC, Ivy SP, Matulonis UA
Gynecol Oncol
May 6, 2024Assessment of socioeconomic and racial differences in patients undergoing concurrent gynecologic oncology and urogynecology surgeries: a National Inpatient Sample (NIS) database study.
Marcu I, McLaughlin EM, Nekkanti S, Khadraoui W, Chalif J, Fulton J, O'Malley D, Chambers LM
Int J Gynecol Cancer
April 25, 2024Bridging the Gap from Bench to Bedside: A Call for In Vivo Preclinical Models to Advance Endometrial Cancer and Cervical Cancer Immuno-Oncology Research.
Chambers L, Haight P, Chalif J, Mehra Y, Spakowicz D, Backes FJ, Cosgrove CM, O'Malley DM, Vargas R, Corr BR, Bae-Jump VL, Arend RC
Clin Cancer Res
April 4, 2024Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279.
Horowitz NS, Deng W, Peterson I, Mannel RS, Thompson S, Lokich E, Myers T, Hanjani P, O'Malley DM, Chung KY, Miller DS, Ueland FR, Dizon DS, Miller A, Mayadev JS, Leath CA, Monk BJ
J Clin Oncol
April 1, 2024Retraction notice to "Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer" [Gynecologic Oncology 183 (2024) 78-84].
Riedinger CJ, Barrington DA, Nagel CI, Khadraoui WK, Haight PJ, Tubbs C, Backes FJ, Cohn DE, O'Malley DM, Copeland LJ, Chambers LM
Gynecol Oncol
March 29, 2024Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer.
Riedinger CJ, Barrington DA, Nagel CI, Khadraoui WK, Haight PJ, Tubbs C, Backes FJ, Cohn DE, O'Malley DM, Copeland LJ, Chambers LM
Gynecol Oncol
March 5, 2024Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.
Richardson DL, Moore KN, Vergote I, Gilbert L, Martin LP, Mantia-Smaldone GM, Castro CM, Provencher D, Matulonis UA, Stec J, Wang Y, Method M, O'Malley DM
Gynecol Oncol
February 29, 2024Diagnosis and management of gastric-type endocervical adenocarcinoma: A case report and review of the literature.
Chalif J, Kistenfeger Q, Fulton J, Morton M, DeVengencie I, Weldemichael W, Vazzano J, O'Malley DM, Chambers LM
Gynecol Oncol
February 1, 2024ISG15 mediates the function of extracellular vesicles in promoting ovarian cancer progression and metastasis.
Dorayappan KDP, Wagner V, Park D, Newcomer MM, Lightfoot MDS, Kalaiyarasan D, Sakaue T, Khadraoui W, Yu L, Wang QE, Maxwell GL, O'Malley D, Pollock RE, Cohn DE, Selvendiran K
J Extracell Biol
January 22, 2024A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial.
Mirza MR, González-Martín A, Graybill WS, O'Malley DM, Gaba L, Stephanie Yap OW, Guerra EM, Rose PG, Baurain JF, Ghamande SA, Denys H, Prendergast E, Pisano C, Follana P, Baumann K, Calvert PM, Korach J, Li Y, Malinowska IA, Gupta D, Monk BJ
Future Oncol
January 22, 2024Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance.
Levine MD, Wang H, Sriram B, Khan A, Senter L, McLaughlin EM, Bixel KL, Chambers LM, Cohn DE, Copeland LJ, Cosgrove CM, Nagel CI, O'Malley DM, Backes FJ
Gynecol Oncol
December 14, 2023Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer.
Bogani G, Coleman RL, Vergote I, van Gorp T, Ray-Coquard I, Oaknin A, Matulonis U, O'Malley D, Raspagliesi F, Scambia G, Monk BJ
Int J Gynecol Cancer
December 7, 2023The microbiome and gynecologic cancer: cellular mechanisms and clinical applications.
Chalif J, Wang H, Spakowicz D, Quick A, Arthur EK, O'Malley D, Chambers LM
Int J Gynecol Cancer
November 8, 2023Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.
Drew Y, Kim JW, Penson RT, O'Malley DM, Parkinson C, Roxburgh P, Plummer R, Im SA, Imbimbo M, Ferguson M, Rosengarten O, Steeghs N, Kim MH, Gal-Yam E, Tsoref D, Kim JH, You B, de Jonge M, Lalisang R, Gort E, Bastian S, Meyer K, Feeney L, Baker N, Ah-See ML, Domchek SM, Banerjee S
Clin Cancer Res
October 25, 2023Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032).
Randall LM, O'Malley DM, Monk BJ, Coleman RL, Gaillard S, Adams S, Duska LR, Dalton H, Holloway RW, Huang M, Chon HS, Cloven NG, ElNaggar AC, O'Cearbhaill RE, Waggoner S, Tarkar A, Striha A, Nelsen LM, Baines A, Samnotra V, Konstantinopoulos PA
Gynecol Oncol
September 26, 2023Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study.
Nakamura Y, Mizuno N, Sunakawa Y, Canon JL, Galsky MD, Hamilton E, Hayashi H, Jerusalem G, Kim ST, Lee KW, Kankeu Fonkoua LA, Monk BJ, Nguyen D, Oh DY, Okines A, O'Malley DM, Pohlmann P, Reck M, Shin SJ, Sudo K, Takahashi S, Van Marcke C, Yu EY, Groisberg R, Ramos J, Tan S, Stinchcombe TE, Bekaii-Saab T
J Clin Oncol
September 21, 2023The impact of antibiotic and proton pump inhibitor use at the time of adjuvant platinum-based chemotherapy on survival in patients with endometrial cancer.
Haight PJ, Kistenfeger Q, Riedinger CJ, Khadraoui W, Backes FJ, Bixel KL, Copeland LJ, Cohn DE, Cosgrove CM, O'Malley DM, Nagel CI, Spakowicz DJ, Chambers LM
Gynecol Oncol
September 4, 2023A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.
Holloway RW, Thaker P, Mendivil AA, Ahmad S, Al-Niaimi AN, Barter J, Beck T, Chambers SK, Coleman RL, Crafton SM, Crane E, Ramez E, Ghamande S, Graybill W, Herzog T, Indermaur MD, John VS, Landrum L, Lim PC, Lucci JA, McHale M, Monk BJ, Moore KN, Morris R, O'Malley DM, Reid TJ, Richardson D, Rose PG, Scalici JM, Silasi DA, Tewari K, Wang EW
Int J Gynecol Cancer
September 4, 2023Low grade serous ovarian cancer: moving the needle.
Morton M, O'Malley D
Int J Gynecol Cancer
August 15, 2023Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib vs Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer.
Grisham RN, Vergote I, Banerjee S, Drill E, Kalbacher E, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Cibula D, Moore KN, Del Campo JM, Berger R, Marth C, Sehouli J, O'Malley DM, Churruca C, Kristensen G, Clamp A, Farley J, Iyer G, Ray-Coquard I, Monk BJ
Clin Cancer Res
July 1, 2023Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO).
Pothuri B, Blank SV, Myers TK, Hines JF, Randall LM, O'Cearbhaill RE, Slomovitz BM, Eskander RN, Alvarez Secord A, Coleman RL, Walker JL, Monk BJ, Moore KN, O'Malley DM, Copeland LJ, Herzog TJ
Gynecol Oncol
June 19, 2023ARTISTRY-7: Phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer.
Herzog TJ, Hays JL, Barlin JN, Buscema J, Cloven NG, Kong LR, Tyagi NK, Lanneau GS, Long BJ, Marsh RL, Seward SM, Starks DC, Welch S, Moore KN, Konstantinopoulos PA, Gilbert L, Monk BJ, O'Malley DM, Chen X, Dalal R, Coleman RL, Sehouli J
Future Oncol
June 15, 2023"More than a song and dance": Exploration of patient perspectives and educational quality of gynecologic cancer content on TikTok.
Morton M, Haight PJ, Khadraoui W, Backes F, Bixel K, O'Malley DM, Nagel C, Chambers LM
Gynecol Oncol
June 1, 2023Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine.
Hendershot A, Slabaugh M, Riaz KM, Moore KN, O'Malley DM, Matulonis U, Konecny GE
Gynecol Oncol Rep
May 11, 2023Tissue factor as a novel diagnostic target for early detection of ovarian cancer using ultrasound microbubbles.
Newcomer MM, Dorayappan KDP, Wagner V, Suarez AA, Calo CA, Kalmar EL, Maxwell GL, O'Malley D, Cohn DE, Tweedle MF, Selvendiran K
Gynecol Oncol
April 20, 2023Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review.
Richardson DL, Eskander RN, O'Malley DM
JAMA Oncol
April 14, 2023Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Mirza MR, González-Martín A, Graybill WS, O'Malley DM, Gaba L, Stephanie Yap OW, Guerra EM, Rose PG, Baurain JF, Ghamande SA, Denys H, Prendergast E, Pisano C, Follana P, Baumann K, Calvert PM, Korach J, Li Y, Malinowska IA, Gupta D, Monk BJ
Cancer
April 8, 2023Glassy cell carcinoma of the cervix: Findings from a combined National Cancer Database analysis and single institution review of treatment patterns and outcomes.
Levine MD, Barrington DA, Meade CE, Lammers SM, McLaughlin EM, Suarez AA, Backes FJ, Copeland LJ, O'Malley DM, Cosgrove CM, Cohn DE, Nagel CI, Felix AS, Bixel KL
Gynecol Oncol
April 1, 2023Use of the Khorana score to predict venous thromboembolism in patients undergoing chemotherapy for uterine cancer.
Piver RN, Wagner VM, Levine MD, Backes FJ, Chambers LJ, Cohn DE, Copeland LJ, Cosgrove CM, Nagel CI, O'Malley DM, Bixel KL
Gynecol Oncol Rep
April 1, 2023Combination lenvatinib plus pembrolizumab in the treatment of ovarian clear cell carcinoma: A case series.
Calo CA, Levine MD, Brown MD, O'Malley DM, Backes FJ
Gynecol Oncol Rep
April 1, 2023Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II?
Levine MD, O'Malley DM, Haight PJ, Senter L, Wagner V, Bixel KL, Cohn DE, Copeland LJ, Cosgrove CM, McLaughlin EM, Backes FJ
Gynecol Oncol Rep
March 29, 2023DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
Arend R, Dholakia J, Castro C, Matulonis U, Hamilton E, Jackson CG, LyBarger K, Goodman HM, Duska LR, Mahdi H, ElNaggar AC, Kagey MH, Liu A, Piper D, Barroilhet LM, Bradley W, Sachdev J, Sirard CA, O'Malley DM, Birrer M
Gynecol Oncol
January 1, 2023Overcoming the challenges of drug development in platinum-resistant ovarian cancer.
Eskander RN, Moore KN, Monk BJ, Herzog TJ, Annunziata CM, O'Malley DM, Coleman RL
Front Oncol
December 24, 2022Postoperative Venous Thromboembolism Risk Stratification in Patients with Uterine Cancer.
Wagner VM, Piver RN, Levine MD, Backes FJ, Chambers LJ, Cohn DE, Copeland LJ, Cosgrove CM, Nagel CI, O'Malley DM, Bixel KL
Am J Obstet Gynecol
December 7, 2022Targeting TMEM205 mediated drug resistance in ovarian clear cell carcinoma using oncolytic virus.
Saini U, Smith BQ, Dorayappan KDP, Yoo JY, Maxwell GL, Kaur B, Konishi I, O'Malley D, Cohn DE, Selvendiran K
J Ovarian Res
October 20, 2022Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
O'Malley DM, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, Swisher EM, Maloney L, Goble S, Lin KK, Kwan T, Ledermann JA, Coleman RL
Gynecol Oncol
October 6, 2022Reply to C. Marchetti et al.
Monk BJ, Fujiwara K, O'Malley DM, Coleman RL, McNeish IA, Lin KK, Hume S, Kristeleit RS
J Clin Oncol
September 22, 2022The contemporary presentation and diagnosis of endometrial cancer recurrence: When, where, and how?
Riedinger CJ, Patterson JM, Backes FJ, O'Malley D, Bixel KL, Copeland LJ, Cohn DE, Goodfellow PJ, Cosgrove CM
Gynecol Oncol
September 1, 2022Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial.
Chase DM, Marín MR, Backes F, Han S, Graybill W, Mirza MR, Pothuri B, Mangili G, O'Malley DM, Berton D, Willmott L, Baumann K, Coleman RL, Safra T, Heinzelmann-Schwarz V, Lorusso D, Karl FM, Woodward T, Monk BJ, Gonzalez-Martin A, PRIMA/ENGOT-OV26/GOG-3012 Investigators
Gynecol Oncol
August 2, 2022Less is more: Clinical utility of postoperative labs following minimally invasive hysterectomy for endometrial cancer.
Lightfoot MDS, Felix AS, Calo CA, Hosmer-Quint JT, Taylor KL, Brown MB, Salani R, Copeland LJ, O'Malley DM, Bixel KL, Cohn DE, Fowler JM, Backes FJ, Cosgrove CM
Am J Obstet Gynecol
August 1, 2022High pre-treatment neutrophil-to-lymphocyte ratio as a prognostic marker for worse survival in patients with recurrent/metastatic cervical cancer treated with immune checkpoint inhibitors.
Calo CA, Barrington DA, Brown M, Gonzalez L, Baek J, Huffman A, Benedict J, Backes F, Chambers L, Cohn D, Copeland L, Cosgrove C, Nagel C, O'Malley D, Bixel K
Gynecol Oncol Rep
June 27, 2022Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study.
Copeland LJ, Brady MF, Burger RA, Rodgers WH, Huang HQ, Cella D, O'Malley DM, Street DG, Tewari KS, Bender DP, Morris RT, Lowery WJ, Miller DS, Dewdney SB, Spirtos NM, Lele SB, Guntupalli S, Ueland FR, Glaser GE, Mannel RS, DiSaia PJ
J Clin Oncol
June 6, 2022A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).
Monk BJ, Parkinson C, Lim MC, O'Malley DM, Oaknin A, Wilson MK, Coleman RL, Lorusso D, Bessette P, Ghamande S, Christopoulou A, Provencher D, Prendergast E, Demirkiran F, Mikheeva O, Yeku O, Chudecka-Glaz A, Schenker M, Littell RD, Safra T, Chou HH, Morgan MA, Drochýtek V, Barlin JN, Van Gorp T, Ueland F, Lindahl G, Anderson C, Collins DC, Moore K, Marme F, Westin SN, McNeish IA, Shih D, Lin KK, Goble S, Hume S, Fujiwara K, Kristeleit RS
J Clin Oncol
May 28, 2022Is there a "Low Risk" Patient Population in Advanced Epithelial Ovarian Cancer?: A Critical Analysis.
Chambers LM, O'Malley DM, Coleman RL, Herzog TJ
Am J Obstet Gynecol
May 9, 2022Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.
O'Cearbhaill RE, Pérez-Fidalgo JA, Monk BJ, Tusquets I, McCormick C, Fuentes J, Moore RG, Vulsteke C, Shahin MS, Forget F, Bradley WH, Hietanen S, O'Malley DM, Dørum A, Slomovitz BM, Baumann K, Selle F, Calvert PM, Artioli G, Levy T, Kumar A, Malinowska IA, Li Y, Gupta D, González-Martín A
Gynecol Oncol
April 20, 2022Practice changing cervical cancer clinical trials.
Pothuri B, Eskander RN, Randall LM, O'Malley DM, Slomovitz B, Moore KN, Herzog TJ, Coleman RL, Copeland LJ, Monk BJ
Gynecol Oncol
February 5, 2022Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.
Gershenson DM, Miller A, Brady WE, Paul J, Carty K, Rodgers W, Millan D, Coleman RL, Moore KN, Banerjee S, Connolly K, Secord AA, O'Malley DM, Dorigo O, Gaillard S, Gabra H, Slomovitz B, Hanjani P, Farley J, Churchman M, Ewing A, Hollis RL, Herrington CS, Huang HQ, Wenzel L, Gourley C
Lancet
January 6, 2022Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.
O'Malley DM, Bariani GM, Cassier PA, Marabelle A, Hansen AR, De Jesus Acosta A, Miller WH, Safra T, Italiano A, Mileshkin L, Xu L, Jin F, Norwood K, Maio M
J Clin Oncol
January 1, 2022Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial.
Barretina-Ginesta MP, Monk BJ, Han S, Pothuri B, Auranen A, Chase DM, Lorusso D, Anderson C, Abadie-Lacourtoisie S, Cloven N, Braicu EI, Amit A, Redondo A, Shah R, Kebede N, Hawkes C, Gupta D, Woodward T, O'Malley DM, González-Martín A
Ther Adv Med Oncol
December 21, 2021Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.
O'Malley DM, Neffa M, Monk BJ, Melkadze T, Huang M, Kryzhanivska A, Bulat I, Meniawy TM, Bagameri A, Wang EW, Doger de Speville Uribe B, Hegg R, Ortuzar Feliu W, Ancukiewicz M, Lugowska I
J Clin Oncol
December 17, 2021Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
Aghajanian C, Swisher EM, Okamoto A, Steffensen KD, Bookman MA, Fleming GF, Friedlander M, Moore KN, Tewari KS, O'Malley DM, Chan JK, Ratajczak C, Hashiba H, Wu M, Dinh MH, Coleman RL
Gynecol Oncol
December 11, 2021Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
Swisher EM, Aghajanian C, O'Malley DM, Fleming GF, Kaufmann SH, Levine DA, Birrer MJ, Moore KN, Spirtos NM, Shahin MS, Reid TJ, Friedlander M, Steffensen KD, Okamoto A, Sehgal V, Ansell PJ, Dinh MH, Bookman MA, Coleman RL
Gynecol Oncol
November 2, 2021Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data.
Arend RC, O'Malley DM, Banerjee S, McLaurin K, Davidson R, Long GH
Adv Ther
November 1, 2021Wound complications following vulvar excision for nonmalignant lesions.
Boyles GP, Weaver AM, Cohn DE, Backes FJ, Copeland LJ, Bixel KL, Fowler JM, O'Malley DM, Cosgrove CM
AJOG Glob Rep
September 30, 2021ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.
Monk BJ, Coleman RL, Fujiwara K, Wilson MK, Oza AM, Oaknin A, O'Malley DM, Lorusso D, Westin SN, Safra T, Herzog TJ, Marmé F, N Eskander R, Lin KK, Shih D, Goble S, Grechko N, Hume S, Maloney L, McNeish IA, Kristeleit RS
Int J Gynecol Cancer
September 30, 2021Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
Swisher EM, Kristeleit RS, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Coleman RL, Burris HA, Aghajanian C, O'Malley DM, Leary A, Welch S, Provencher D, Shapiro GI, Chen LM, Shapira-Frommer R, Kaufmann SH, Goble S, Maloney L, Kwan T, Lin KK, McNeish IA
Gynecol Oncol
September 21, 2021Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety.
Oaknin A, Oza AM, Lorusso D, Aghajanian C, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Amenedo Gancedo M, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Ledermann JA, Coleman RL
Cancer Med
September 11, 2021Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).
Gaillard S, Oaknin A, Ray-Coquard I, Vergote I, Scambia G, Colombo N, Fernandez C, Alfaro V, Kahatt C, Nieto A, Zeaiter A, Aracil M, Vidal L, Pardo-Burdalo B, Papai Z, Kristeleit R, O'Malley DM, Benjamin I, Pautier P, Lorusso D
Gynecol Oncol
August 25, 2021Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II.
Oonk MHM, Slomovitz B, Baldwin PJW, van Doorn HC, van der Velden J, de Hullu JA, Gaarenstroom KN, Slangen BFM, Vergote I, Brännström M, van Dorst EBL, van Driel WJ, Hermans RH, Nunns D, Widschwendter M, Nugent D, Holland CM, Sharma A, DiSilvestro PA, Mannel R, Boll D, Cibula D, Covens A, Provencher D, Runnebaum IB, Luesley D, Ellis P, Duncan TJ, Tjiong MY, Cruickshank DJ, Kjølhede P, Levenback CF, Bouda J, Kieser KE, Palle C, Spirtos NM, O'Malley DM, Leitao MM, Geller MA, Dhar K, Asher V, Tamussino K, Tobias DH, Borgfeldt C, Lea JS, Bailey J, Lood M, Eyjolfsdottir B, Attard-Montalto S, Tewari KS, Manchanda R, Jensen PT, Persson P, Van Le L, Putter H, de Bock GH, Monk BJ, Creutzberg CL, van der Zee AGJ
J Clin Oncol
August 24, 2021Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
O'Malley DM, Oaknin A, Monk BJ, Selle F, Rojas C, Gladieff L, Berton D, Leary A, Moore KN, Estevez-Diz MDP, Hardy-Bessard AC, Alexandre J, Opperman CP, de Azevedo CRAS, Randall LM, Feliu WO, Ancukiewicz M, Ray-Coquard I
Gynecol Oncol
August 19, 2021RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer.
O'Malley DM, Randall LM, Jackson CG, Coleman RL, Hays JL, Moore KN, Naumann RW, Rocconi RP, Slomovitz BM, Tewari KS, Ancukiewicz M, Feliu WO, Monk BJ
Future Oncol
August 17, 2021Endometrial Cancer: Who lives, who dies, can we improve their story?
Cosgrove CM, Backes FJ, O'Malley D, Bixel KL, Suarez AA, Fowler JM, Copeland LJ, Goodfellow PJ, Cohn DE
Oncologist
July 13, 2021Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer.
Backes FJ, Wei L, Chen M, Hill K, Dzwigalski K, Poi M, Phelps M, Salani R, Copeland LJ, Fowler JM, Cohn DE, Bixel K, Cosgrove C, Hays J, O'Malley D
Gynecol Oncol
June 30, 2021Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab.
Makker V, Taylor MH, Oaknin A, Herraez AC, Orlowski R, Dutta L, Ren M, Zale M, O'Malley DM
Oncologist
June 14, 2021Progress in Gynecologic Cancers with Antibody Drug Conjugates.
O'Malley DM, Calo CA
Curr Oncol Rep
June 8, 2021Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3.
Clamp AR, Lorusso D, Oza AM, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Scambia G, Leary A, Holloway RW, Amenedo Gancedo M, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Goble S, Coleman RL, Ledermann JA
Int J Gynecol Cancer
June 2, 2021Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
Alvarez Secord A, O'Malley DM, Sood AK, Westin SN, Liu JF
Gynecol Oncol
May 3, 2021Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).
Swisher EM, Kwan TT, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Coleman RL, Aghajanian C, Konecny GE, O'Malley DM, Leary A, Provencher D, Welch S, Chen LM, Wahner Hendrickson AE, Ma L, Ghatage P, Kristeleit RS, Dorigo O, Musafer A, Kaufmann SH, Elvin JA, Lin DI, Chambers SK, Dominy E, Vo LT, Goble S, Maloney L, Giordano H, Harding T, Dobrovic A, Scott CL, Lin KK, McNeish IA
Nat Commun
April 10, 2021Postoperative complications after non-obstetric surgery among pregnant patients in the National Surgical Quality Improvement Program, 2005-2012.
Abdelwahab M, Lynch CD, Schneider P, Thung S, Costantine MM, O'Malley D, Landon MB, Pawlik TM, Venkatesh KK
Am J Surg
March 19, 2021Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
Konecny GE, Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, Ray-Coquard I, Aghajanian C, Coleman RL, O'Malley DM, Leary A, Chen LM, Provencher D, Ma L, Brenton JD, Castro C, Green M, Simmons AD, Beltman J, Harding T, Lin KK, Goble S, Maloney L, Kristeleit RS, McNeish IA, Swisher EM, Xiao JJ
Gynecol Oncol
March 12, 2021The GOG partners: A program for industry sponsored clinical trials in gynecologic oncology within the GOG foundation.
Monk BJ, Coleman RL, Herzog TJ, Moore KN, O'Malley DM, Randall LM, Slomovitz BM, Eskander R, Pothuri B, Reese LL, Mannel RS, Copeland LJ
Gynecol Oncol
March 9, 2021Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).
Buechel ME, Enserro D, Burger RA, Brady MF, Wade K, Secord AA, Nixon AB, Mirniaharikandehei S, Liu H, Zheng B, O'Malley DM, Gray H, Tewari KS, Mannel RS, Birrer MJ, Moore KN
Gynecol Oncol
February 2, 2021Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA, Liu J, Mahdi H, Martin L, Matei D, McHale M, McLean K, Miller DS, O'Malley DM, Percac-Lima S, Ratner E, Remmenga SW, Vargas R, Werner TL, Zsiros E, Burns JL, Engh AM
J Natl Compr Canc Netw
January 1, 2021Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients.
Hampel H, Pearlman R, de la Chapelle A, Pritchard CC, Zhao W, Jones D, Yilmaz A, Chen W, Frankel WL, Suarez AA, Cosgrove C, Backes F, Copeland L, Fowler J, O'Malley D, Salani R, McElroy JP, Stanich PP, Goodfellow P, Cohn DE
Gynecol Oncol
September 17, 2020A clinical classification system for grading platinum hypersensitivity reactions.
Vetter MH, Castaneda A, Khan A, O'Malley DM
Gynecol Oncol
September 1, 2020Pathologic chemotherapy response score in epithelial ovarian cancer: Surgical, genetic, and survival considerations.
Barrington DA, Felix AS, Owda R, Suarez AA, Cohen DW, Senter L, Copeland LJ, Fowler JM, Backes FJ, Cohn DE, Bixel KL, O'Malley DM, Salani R, Cosgrove CM
Surg Oncol
August 24, 2020Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.
Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cella D, Meunier J, Goble S, Cameron T, Maloney L, Mörk AC, Bedel J, Ledermann JA, Coleman RL
J Clin Oncol
August 21, 2020MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
Monk BJ, Grisham RN, Banerjee S, Kalbacher E, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Drill E, Cibula D, Moore KN, Christy-Bittel J, Del Campo JM, Berger R, Marth C, Sehouli J, O'Malley DM, Churruca C, Boyd AP, Kristensen G, Clamp A, Ray-Coquard I, Vergote I
J Clin Oncol
August 1, 2020Positive sentinel lymph node in a patient with clinical stage I vaginal cancer.
Montemorano L, Vetter MH, Blumenfeld M, O'Malley DM
Gynecol Oncol Rep
July 31, 2020The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma.
Colombo N, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Meunier J, Cameron T, Maloney L, Goble S, Bedel J, Ledermann JA, Coleman RL
Gynecol Oncol
June 29, 2020Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.
Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O'Malley DM, Backes FJ, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD
Clin Cancer Res
June 5, 2020Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study.
Hamilton E, O'Malley DM, O'Cearbhaill R, Cristea M, Fleming GF, Tariq B, Fong A, French D, Rossi M, Brickman D, Moore K
Gynecol Oncol
May 28, 2020Antibody-drug conjugates for the treatment of ovarian cancer.
Calo CA, O'Malley DM
Expert Opin Biol Ther
May 1, 2020Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Coleman RL
Lancet Oncol
April 29, 2020COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies.
Monk BJ, Coleman RL, Moore KN, Herzog TJ, Secord AA, Matulonis UA, Slomovitz BM, Guntupalli SR, O'Malley DM
Gynecol Oncol
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. O'Malley has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.
- AstraZeneca
- GlaxoSmithKline
- Novocure
- Regeneron Pharmaceuticals
- GOG Foundation, Inc.
- Seagen
- Zentalis Pharmaceuticals, Inc
- Genelux
- Merck Sharp & Dohme
Patient Comments
Very impressed with Dr O'Malley, Courtney and staff. Genuinely caring and compassionate. Very informative and explain processes.
I was given so much information and shown pictures that really explained my cancer and being given that knowledge meant everything to me
I was very apprehensive about going to the James, upon meeting Dr. O'Malley the very first time, I knew I would be in good hands. My fears were gone. I thank God every day for him.
Best people to have ever met and trust in my time of need
Excellent
Would like to give excellent instead of good. Dr O'Malley was wonderful
Dr.O' Malley and Courtney Arn are excellent care providers. I always feel comfortable asking any questions and know they will give me direct answers. I feel very blessed to be under their care.
Exceptional care,
Made me feel I am in capable hands looking out for my best interest
Dr O'Malley is extremely personable and remembers family to inquire about. He is professional and elite in his field.
Attentive and Respectful
Dr. O'Malley and his staff are the absolute best in the business
I was treated with much concern and Staff was very helpful
Great
I wish there was something higher than a 5. Dr Omalley and his team are consistently amazing.
Excellent care
Overall experience with care team, very good all questions and concerns answered
Dr O'Malley is always very attentive, answers my questions, gives me a complete update of my scans and treatment. I feel extremely comfortable with him and his staff.
Honest diagnosis and confidence of care options by expert provided understanding and hope to this terrified person facing this thief in the night!
I have trusted my care provider with my life 3 times and I would never go any where else or see any one else.
Excellent experience
Dr. O' Malley is very nice and patient.
Dr. O'Malley and his NP, Courtney Arn are the best!
I felt very comfortable when Dr. OMalley walked in the room to introduce himself and do my examination. He gave me the impression that he truly cared about me. And answered all my questions.
Dr. O'Malley is always very friendly, considerate, compassionate and caring. He answers questions no matter how silly they may seem to me. He is very professional but also extremely likable. He always addresses my concerns promptly and is willing to find the answer if he's not sure. I trust this doctor with my life.
I am happy with my care.
Dr O'Malley is awesome I know I will get the best care possible
God put Dr. O'Malley in my life to save my life. I have no doubt that if I hadn't been treated by Dr O'Malley I would be deceased.
The entire staff is superior. Courtney Arn, NP and Dr. David O'Malley are truly the best!
The care I get from my Dr. And NP is unparalleled. I was living in another state when diagnosed and moved to Ohio and the James mid treatment. I am originally from Ohio.
I totally trust Dr O'Malley and his staff. There is no one better
You really need a choice of beyond excellence for Dr. O Malley
Excellent
Dr.Omallly has also be very thorough and fiull of information. Feel very confident in his work and a patient of his.
Dr O'Malley is an exceptional outstanding caring doctor!! He saved my life and I am forever grateful. He is my SuperHero!!Best Doctor I have ever met.
Excellent job. Thank you for giving me the chance to live again!
Courtney Arn & Dr. O'Malley have my utmost appreciation for their care and concern about my situation and treatment. I honestly feel that I would not be in the place I am with my journey without them. Excellent treatment, excellent communication, excellent care!
Provider is VERY knowledgeable and explains all but doesn't discuss treatment plans (I'm not sure there are options)!
Good
I trust my oncologist and the NP completely. They keep themselves informed of new treatments that could be effective and share that info with me.
Very thorough.
Honest, compassionate and personable.
My appointment was close to 2 hours from start to finish. Care received by providers was compassionate & understanding.